Aadi Bioscience Statistics
Total Valuation
Aadi Bioscience has a market cap or net worth of $53.98 million. The enterprise value is -$7.20 million.
Important Dates
The next estimated earnings date is Monday, March 17, 2025, before market open.
| Earnings Date | Mar 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Aadi Bioscience has 24.65 million shares outstanding. The number of shares has increased by 0.38% in one year.
| Current Share Class | 24.65M |
| Shares Outstanding | 24.65M |
| Shares Change (YoY) | +0.38% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 15.02% |
| Owned by Institutions (%) | 25.97% |
| Float | 9.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.38 |
| Forward PS | n/a |
| PB Ratio | 0.79 |
| P/TBV Ratio | 0.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.89, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.89 |
| Quick Ratio | 4.37 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -301.35 |
Financial Efficiency
Return on equity (ROE) is -65.95% and return on invested capital (ROIC) is -41.97%.
| Return on Equity (ROE) | -65.95% |
| Return on Assets (ROA) | -35.27% |
| Return on Invested Capital (ROIC) | -41.97% |
| Return on Capital Employed (ROCE) | -90.99% |
| Revenue Per Employee | $281,685 |
| Profits Per Employee | -$693,112 |
| Employee Count | 89 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 11.58 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.03% in the last 52 weeks. The beta is 0.34, so Aadi Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +4.03% |
| 50-Day Moving Average | 2.90 |
| 200-Day Moving Average | 2.11 |
| Relative Strength Index (RSI) | 29.91 |
| Average Volume (20 Days) | 106,350 |
Short Selling Information
The latest short interest is 764,364, so 3.10% of the outstanding shares have been sold short.
| Short Interest | 764,364 |
| Short Previous Month | 706,434 |
| Short % of Shares Out | 3.10% |
| Short % of Float | 7.85% |
| Short Ratio (days to cover) | 5.46 |
Income Statement
In the last 12 months, Aadi Bioscience had revenue of $25.07 million and -$61.69 million in losses. Loss per share was -$2.28.
| Revenue | 25.07M |
| Gross Profit | -27.54M |
| Operating Income | -63.59M |
| Pretax Income | -65.44M |
| Net Income | -61.69M |
| EBITDA | -63.40M |
| EBIT | -63.59M |
| Loss Per Share | -$2.28 |
Full Income StatementBalance Sheet
The company has $62.62 million in cash and $946,000 in debt, giving a net cash position of $61.67 million or $2.50 per share.
| Cash & Cash Equivalents | 62.62M |
| Total Debt | 946,000 |
| Net Cash | 61.67M |
| Net Cash Per Share | $2.50 |
| Equity (Book Value) | 68.87M |
| Book Value Per Share | 2.80 |
| Working Capital | 61.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$54.14 million and capital expenditures -$2.28 million, giving a free cash flow of -$56.43 million.
| Operating Cash Flow | -54.14M |
| Capital Expenditures | -2.28M |
| Free Cash Flow | -56.43M |
| FCF Per Share | -$2.29 |
Full Cash Flow StatementMargins
Gross margin is -109.86%, with operating and profit margins of -253.63% and -246.06%.
| Gross Margin | -109.86% |
| Operating Margin | -253.63% |
| Pretax Margin | -246.06% |
| Profit Margin | -246.06% |
| EBITDA Margin | -252.87% |
| EBIT Margin | -253.63% |
| FCF Margin | n/a |
Dividends & Yields
Aadi Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.38% |
| Shareholder Yield | -0.38% |
| Earnings Yield | -113.25% |
| FCF Yield | -103.59% |
Analyst Forecast
The average price target for Aadi Bioscience is $1.75, which is -20.09% lower than the current price. The consensus rating is "Hold".
| Price Target | $1.75 |
| Price Target Difference | -20.09% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 43.96% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Aadi Bioscience has an Altman Z-Score of -4.33 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.33 |
| Piotroski F-Score | 2 |